Omeprazole Pinewood Laboratories

Omeprazole, the active ingredient in Omeprazole Pinewood Laboratories, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazole Pinewood Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to manage acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - NSAID‑associated gastropathy: lowers incidence of ulcer formation. - Helicobacter pylori eradication regimens: enhances effectiveness of antibiotic therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild and transient. - Diarrhea: usually self‑limiting. - Nausea: occasional mild discomfort. - Abdominal pain: mild cramping. - Flatulence: increased gas. - Constipation: occasional bowel change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Hypomagnesemia: low magnesium levels. - Osteoporotic fractures: increased risk with long‑term use. - Stevens‑Johnson syndrome: rare severe skin reaction. - Liver enzyme elevation: potential hepatic impact.

When prescribing Omeprazole, consider the following safety measures: - Assess renal function: adjust use in severe impairment. - Review hepatic status: use cautiously in liver disease. - Evaluate long‑term need: limit duration to the shortest effective period. - Monitor electrolytes: watch for magnesium depletion with prolonged therapy. - Counsel on infection risk: inform patients about possible C. difficile symptoms. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the plasma concentration of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased antiviral absorption, risking treatment failure. - Dasatinib: lowered exposure, potentially reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, requiring INR monitoring. - Phenytoin: increased metabolism, possibly lowering seizure control. - Methotrexate: reduced clearance, risk of toxicity. - Ketoconazole: decreased absorption, may need dose adjustment.